Pfizer and BioNTech will begin trials of their updated mRNA Covid-19 vaccine designed to protect against the newer BA.4 and BA.5 sub-variants of the coronavirus later this month.
for the second quarter of 2022, where the German vaccine maker reported a total revenue of €3.2 billion —lower than analyst estimates.
BioNTech and its American partner Pfizer have started manufacturing “bivalent” Omicron BA.1 and BA.4/BA.5 vaccines that will offer protections both against the fast spreading newer variants and earlier variants, the company said. The company claims it will be able roll out the updated shots by October—in time for potential fall boosters—if it receives regulatory approval.
Pfizer and BioNTech have already carried out clinical trials for their BA.1 Omicron-focussed vaccine—it was shown to produce higher neutralizing antibodies against the variant—and have submitted the findings to regulators.submit updated clinical trial data for the BA.4/BA.5 adapted shots. The agency will instead approve the modified vaccines using clinical data from the BA.1 vaccine trials. This will allow the updated vaccines to be approved quicker.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Vaccine Targeting Fast-Spreading Omicron Subvariants Could Be Ready For Fall As Pfizer, BioNTech Announce TrialsPfizer and BioNTech will begin trials of their updated mRNA Covid-19 vaccine designed to protect against the newer BA.4 and BA.5 sub-variants of the coronavirus later this month.
Read more »
Pfizer just started a late-stage clinical trial of a Lyme disease vaccineIf the trial succeeds, the vaccine could be the first human immunization for Lyme disease in the U.S. in two decades.
Read more »
Pfizer to buy South SF-based Global Blood Therapeutics in $5.4B dealPfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.
Read more »
Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln dealPfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics , as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.
Read more »
Pfizer Agrees to $5.4 Billion Deal for Global Blood TherapeuticsPfizer has agreed to buy Global Blood Therapeutics for $5.4 billion, a deal that will give the big drugmaker a foothold in the treatment of sickle-cell disease.
Read more »
Pfizer buying spree continues with $5.4B hematology dealPfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic.
Read more »